IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas von HOUILLIER, C, WANG, X, HOANG-XUAN, K, SANSON, M, DELATTRE, J.-Y, KALOSHI, G, MOKHTARI, K, GUILLEVIN, R, LAFFAIRE, J, PARIS, S, BOISSELIER, B, IDBAIH, A, LAIGLE-DONADEY, F

Volltext

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 von LABUSSIERE, M, IDBAIH, A, DUCRAY, F, EL HALLANI, S, MOKHTARI, K, HOANG-XUAN, K, DELATTRE, J.-Y, SANSON, M, WANG, X.-W, MARIE, Y, BOISSELIER, B, FALET, C, PARIS, S, LAFFAIRE, J, CARPENTIER, C, CRINIERE, E

Volltext

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations von Labussière, M, Di Stefano, A L, Gleize, V, Boisselier, B, Giry, M, Mangesius, S, Bruno, A, Paterra, R, Marie, Y, Rahimian, A, Finocchiaro, G, Houlston, R S, Hoang-Xuan, K, Idbaih, A, Delattre, J-Y, Mokhtari, K, Sanson, M

Volltext

Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience von Ducray, F., Demarquay, G., Graus, F., Decullier, E., Antoine, J.-C., Giometto, B., Psimaras, D., Delattre, J.-Y., Carpentier, A. F., Honnorat, J.

Volltext

Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity von Viotti, J, Duplan, E, Caillava, C, Condat, J, Goiran, T, Giordano, C, Marie, Y, Idbaih, A, Delattre, J-Y, Honnorat, J, Checler, F, Alves da Costa, C

Volltext

The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20 von Postma, T.J., Aaronson, N.K., Heimans, J.J., Muller, M.J., Hildebrand, J.G., Delattre, J.Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., Moynihan, C., Maher, J., Lucey, R.

Volltext

Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome von KALOSHI, G, BENOUAICH-AMIEL, A, CAPELLE, L, DUFFAU, H, CORNU, P, SIMON, J.-M, MOKHTARI, K, POLIVKA, M, OMURO, A, CARPENTIER, A, SANSON, M, DELATTRE, J.-Y, DIAKITE, F, HOANG-XUAN, K, TAILLIBERT, S, LEJEUNE, J, LAIGLE-DONADEY, F, RENARD, M.-A, IRAQI, W, IDBAIH, A, PARIS, S

Volltext

Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions von HOANG-XUAN, K, CAPELLE, L, CARPENTIER, A. F, LAIGLE, F, SIMON, J. M, CORNU, P, BROËT, P, SANSON, M, DELATTRE, J. Y, KUJAS, M, TAILLIBERT, S, DUFFAU, H, LEJEUNE, J, POLIVKA, M, CRINIERE, E, MARIE, Y, MOKHTARI, K

Volltext

Adult brainstem glioma presenting with isolated persistent hemifacial spasm or facial nerve palsy von Dudoit, T., Balossier, A., Reyes-Botero, G., Laigle-Donadey, F., Emery, E., Blond, S., Carluer, L., Lechapt-Zalcman, E., Delattre, J.-Y., Guillamo, J.-S.

Volltext

Recommended diagnostic criteria for paraneoplastic neurological syndromes von Graus, F, Delattre, J Y, Antoine, J C, Dalmau, J, Giometto, B, Grisold, W, Honnorat, J, Smitt, P Sillevis, Vedeler, Ch, Verschuuren, J J G M, Vincent, A, Voltz, R

Volltext

Address from the previous President, January 2017 von Delattre, J.-Y.

Volltext

Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone von Keime-Guibert, F, Graus, F, Fleury, A, René, R, Honnorat, J, Broet, P, Delattre, J-Y

Volltext

Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and... von HOANG-XUAN, K, TAILLANDIER, L, CHINOT, O, SOUBEYRAN, P, BOGDHAN, U, HILDEBRAND, J, FRENAY, M, DE BEULE, N, DELATTRE, J. Y, BARON, B

Volltext

Address from the President, January 2016 von Delattre, J.-Y.

Volltext

Adress from the President, January 2016 von Delattre, J-Y

Volltext

Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies von ROJAS, I, GRAUS, F, KEIME-GUIBERT, F, RENE, R, DELATTRE, J. Y, RAMON, J. M, DALMAU, J, POSNER, J. B

Volltext

Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222 von Enciso-Mora, V, Hosking, F J, Di Stefano, A L, Zelenika, D, Shete, S, Broderick, P, Idbaih, A, Delattre, J-Y, Hoang-Xuan, K, Marie, Y, Labussière, M, Alentorn, A, Ciccarino, P, Rossetto, M, Armstrong, G, Liu, Y, Gousias, K, Schramm, J, Lau, C, Hepworth, S J, Schoemaker, M, Strauch, K, Müller-Nurasyid, M, Schreiber, S, Franke, A, Moebus, S, Eisele, L, Swerdlow, A, Simon, M, Bondy, M, Lathrop, M, Sanson, M, Houlston, R S

Volltext

T cell response to Hu-D peptides in patients with anti-Hu syndrome von ROUSSEAU, A, BENYAHIA, B, DALMAU, J, CONNAN, F, GUILLET, J.-G, DELATTRE, J.-Y, CHOPPIN, J

Volltext

Initial chemotherapy in gliomatosis cerebri von SANSON, M, CARTALAT-CAREL, S, TAILLANDIER, L, CHINOT, O, DUFFAU, H, HONNORAT, J, HOANG-XUAN, K, DELATTRE, J. Y, TAILLIBERT, S, NAPOLITANO, M, DJAFARI, L, COUGNARD, J, GERVAIS, H, LAIGLE, F, CARPENTIER, A, MOKHTARI, K

Volltext

EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force von Soffietti, R., Cornu, P., Delattre, J. Y., Grant, R., Graus, F., Grisold, W., Heimans, J., Hildebrand, J., Hoskin, P., Kalljo, M., Krauseneck, P., Marosi, C., Siegal, T., Vecht, C.

Volltext